NCT07485647 2026-03-20
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Vanderbilt-Ingram Cancer Center
Phase 2 Not yet recruiting
Vanderbilt-Ingram Cancer Center
Regeneron Pharmaceuticals
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.